Organization (Industry)
CareDx, Inc.
ClinicalTrials.gov lists CareDx, Inc. as lead sponsor of 15 trials. It has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers CareDx, Inc.: 15 lead-sponsored trials and 4 legal-entity registrations.
Disease areas (14)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| COVID-19 | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Myelodysplastic Syndromes | 2 |
| Renal Insufficiency, Chronic | 2 |
| Acute Kidney Injury | 1 |
Showing 5 of 14 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2022 | 1 |
| 2021 | 8 |
| 2020 | 8 |
| 2019 | 2 |
| 2018 | 2 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 1 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: none of the 20 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| MMF | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 33% hit target (n=6) | 2 of 4 on time (n=4) |
Journals published in (31)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation | 13 |
| American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons | 7 |
| Transplantation | 6 |
| American journal of respiratory and critical care medicine | 2 |
| Clinical transplantation | 2 |
Showing 5 of 31 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 31 | 2 | 2025-09-02 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 379,805,000 | -21,354,000 | 71,429,000 |
| 2024 | 333,785,000 | 52,549,000 | 72,510,000 |
| 2023 | 280,324,000 | -190,284,000 | 82,421,000 |
| 2022 | 321,793,000 | -76,613,000 | 90,388,000 |
| 2021 | 296,397,000 | -30,662,000 | 76,525,000 |
| 2020 | 192,194,000 | -18,714,000 | 48,941,000 |
| 2019 | 127,068,000 | -21,968,000 | 30,711,000 |
| 2018 | 76,569,000 | -46,756,000 | 14,514,000 |
| 2017 | 48,324,000 | -55,469,000 | 12,388,000 |
| 2016 | 40,631,000 | -39,469,000 | 12,385,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (15)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-04-24 | Other financing | not disclosed | Sec extracted |
| 2026-04-15 | Other financing | not disclosed | Sec extracted |
| 2025-05-30 | Other financing | not disclosed | Sec extracted |
| 2023-05-10 | Other financing | not disclosed | Edgar offerings |
| 2023-03-29 | Royalty / licensing | not disclosed | Sec extracted |
Showing 5 of 15 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 2 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| CareDx, Inc. | BRISBANE, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (83)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-24 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-15 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 83 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| CAREDX, INC | Certificate of accreditation | Active |
Biomarker capability evidence (28)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABO | Trial collaborator | Named in trial inclusion criteria |
| CABIN1 | Trial collaborator | Named in trial inclusion criteria |
| CAV1 | Trial sponsor | Named in trial inclusion criteria |
| CD34 | Trial sponsor | Named in trial inclusion criteria |
| DCD | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 28 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, fda warning letters, fda untitled letters, fda recalls, fda import refusals, organization relationships, and biomarkers this organization publishes on.